Viral vectored granulocyte-macrophage colony stimulating factor inhibits vaccine protection in an SIV challenge model: Protection correlates with neutralizing antibody

Vaccine

Volumn 30, Issue 28, 2012, Pages 4233-4239

  Schell, John B ^a   Bahl, Kapil ^a   Rose, Nina F ^a   Buonocore, Linda ^a   Hunter, Meredith ^b   Marx, Preston A ^b   LaBranche, Celia C ^c   Montefiori, David C ^c   Rose, John K ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cytokine adjuvant; Rhesus macaques; SIV vaccine; SIVsmE660 challenge

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; GAG PROTEIN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; NEUTRALIZING ANTIBODY; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; UNCLASSIFIED DRUG; VESICULAR STOMATITIS VIRUS VECTOR; VIRUS ANTIGEN; VIRUS ENVELOPE PROTEIN; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; ENVELOPE GENE; GENE EXPRESSION; GROUP SPECIFIC ANTIGEN GENE; IMMUNIZATION; MACACA; MUCOSAL IMMUNITY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REPLICON; SIMIAN IMMUNODEFICIENCY VIRUS; VESICULAR STOMATITIS VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRUS GENE; VIRUS LOAD; VIRUS NEUTRALIZATION; VIRUS PARTICLE; VIRUS REPLICATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; GENETIC VECTORS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; IMMUNITY, MUCOSAL; MACACA MULATTA; SAIDS VACCINES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; VESICULOVIRUS;

EID: 84861689190     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.04.046     Document Type: Article

References (34)

1. Ahlers J.D., Dunlop N., Alling D.W., Nara P.L., Berzofsky J.A. Cytokine-in-adjuvant steering of the immune response phenotype to HIV-1 vaccine constructs: granulocyte-macrophage colony-stimulating factor and TNF-alpha synergize with IL-12 to enhance induction of cytotoxic T lymphocytes. Journal of Immunology 1997, 158:3947-3958.
2. Bowne W.B., Wolchok J.D., Hawkins W.G., Srinivasan R., Gregor P., Blachere N.E., et al. Injection of DNA encoding granulocyte-macrophage colony-stimulating factor recruits dendritic cells for immune adjuvant effects. Cytokines, Cellular and Molecular Therapy 1999, 5:217-225.
3. Brandsma J.L., Shylankevich M., Su Y., Roberts A., Rose J.K., Zelterman D., et al. Vesicular stomatitis virus-based therapeutic vaccination targeted to the E1, E2 E6, and E7 proteins of cottontail rabbit papillomavirus. Journal of Virology 2007, 81:5749-5758.
4. Bukreyev A., Belyakov I.M., Berzofsky J.A., Murphy B.R., Collins P.L. Granulocyte-macrophage colony-stimulating factor expressed by recombinant respiratory syncytial virus attenuates viral replication and increases the level of pulmonary antigen-presenting cells. Journal of Virology 2001, 75:12128-12140.
5. Chattopadhyay A., Park S., Delmas G., Suresh R., Senina S., Perlin D.S., et al. Single-dose, virus-vectored vaccine protection against Yersinia pestis challenge: CD4+cells are required at the time of challenge for optimal protection. Vaccine 2008, 26:6329-6337.
6. Chattopadhyay A., Rose J.K. Complementing defective viruses that express separate paramyxovirus glycoproteins provide a new vaccine vector approach. Journal of Virology 2011, 85:2004-2011.
7. Cobleigh M.A., Buonocore L., Uprichard S.L., Rose J.K., Robek M.D. A vesicular stomatitis virus-based hepatitis B virus vaccine vector provides protection against challenge in a single dose. Journal of Virology 2010, 84:7513-7522.
8. Cooper D., Wright K.J., Calderon P.C., Guo M., Nasar F., Johnson J.E., et al. Attenuation of recombinant vesicular stomatitis virus-human immunodeficiency virus type 1 vaccine vectors by gene translocations and g gene truncation reduces neurovirulence and enhances immunogenicity in mice. Journal of Virology 2008, 82:207-219.
9. Evans D.T., Jing P., Allen T.M., O'Connor D.H., Horton H., Venham J.E., et al. Definition of five new simian immunodeficiency virus cytotoxic T-lymphocyte epitopes and their restricting major histocompatibility complex class I molecules: evidence for an influence on disease progression. Journal of Virology 2000, 74:7400-7410.
10. Faderl S., Harris D., Van Q., Kantarjian H.M., Talpaz M., Estrov Z. Granulocyte-macrophage colony-stimulating factor (GM-CSF) induces antiapoptotic and proapoptotic signals in acute myeloid leukemia. Blood 2003, 102:630-637.
11. Geisbert T.W., Feldmann H. Recombinant vesicular stomatitis virus-based vaccines against ebola and marburg virus infections. Journal of Infectious Diseases 2011, 204(Suppl. 3):S1075-S1081.
12. Keele B.F., Li H., Learn G.H., Hraber P., Giorgi E.E., Grayson T., et al. Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. Journal of Experimental Medicine 2009, 206:1117-1134.
13. Kitamura T., Tange T., Terasawa T., Chiba S., Kuwaki T., Miyagawa K., et al. Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF IL-3, or erythropoietin. Journal of Cellular Physiology 1989, 140:323-334.
14. + CD8(+) T cells, but loss of interferon-gamma+ HIV-specific T cells during progression to AIDS. Blood 2002, 99:2505-2511.
15. Lai L., Kwa S., Kozlowski P.A., Montefiori D.C., Ferrari G., Johnson W.E., et al. Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine. Journal of Infectious Diseases 2011, 204:164-173.
16. Lai L., Vodros D., Kozlowski P.A., Montefiori D.C., Wilson R.L., Akerstrom V.L., et al. GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89. 6P challenge by a DNA/MVA immunodeficiency virus vaccine. Virology 2007, 369:153-167.
17. Lechner M.G., Liebertz D.J., Epstein A.L. Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. Journal of Immunology 2010, 185:2273-2284.
18. Letvin N.L., Rao S.S., Montefiori D.C., Seaman M.S., Sun Y., Lim S.Y., et al. Immune and genetic correlates of vaccine protection against mucosal infection by SIV in monkeys. Science Translational Medicine 2011, 3(81):ra36.
19. Li M., Gao F., Mascola J.R., Stamatatos L., Polonis V.R., Koutsoukos M., et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. Journal of Virology 2005, 79:10108-10125.
20. Min L., Mohammad Isa S.A., Shuai W., Piang C.B., Nih F.W., Kotaka M., et al. Cutting edge: granulocyte-macrophage colony-stimulating factor is the major CD8+ T cell-derived licensing factor for dendritic cell activation. Journal of Immunology 2010, 184:4625-4629.
21. O'Connor D.H., Mothe B.R., Weinfurter J.T., Fuenger S., Rehrauer W.M., Jing P., et al. Major histocompatibility complex class I alleles associated with slow simian immunodeficiency virus disease progression bind epitopes recognized by dominant acute-phase cytotoxic-T-lymphocyte responses. Journal of Virology 2003, 77:9029-9040.
22. Ramsburg E., Publicover J., Buonocore L., Poholek A., Robek M., Palin A., et al. A vesicular stomatitis virus recombinant expressing granulocyte-macrophage colony-stimulating factor induces enhanced T-cell responses and is highly attenuated for replication in animals. Journal of Virology 2005, 79:15043-15053.
23. Ramsburg E., Rose N.F., Marx P.A., Mefford M., Nixon D.F., Moretto W.J., et al. Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol. Journal of Virology 2004, 78:3930-3940.
24. Reynolds M.R., Sacha J.B., Weiler A.M., Borchardt G.J., Glidden C.E., Sheppard N.C., et al. The TRIM5{alpha} genotype of rhesus macaques affects acquisition of simian immunodeficiency virus SIVsmE660 infection after repeated limiting-dose intrarectal challenge. Journal of Virology 2011, 85:9637-9640.
25. Rose N.F., Marx P.A., Luckay A., Nixon D.F., Moretto W.J., Donahoe S.M., et al. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 2001, 106:539-549.
26. Rose N.F., Roberts A., Buonocore L., Rose J.K. Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1. Journal of Virology 2000, 74:10903-10910.
27. Schell J.B., Rose N.F., Bahl K., Diller K., Buonocore L., Hunter M., et al. Significant protection against high-dose simian immunodeficiency virus challenge conferred by a new prime-boost vaccine regimen. Journal of Virology 2011, 85:5764-5772.
28. Schneider T., Jahn H.U., Schmidt W., Riecken E.O., Zeitz M., Ullrich R. Loss of CD4 T lymphocytes in patients infected with human immunodeficiency virus type 1 is more pronounced in the duodenal mucosa than in the peripheral blood Berlin diarrhea/wasting syndrome study group. Gut 1995, 37:524-529.
29. Schwartz J.A., Buonocore L., Suguitan A., Hunter M., Marx P.A., Subbarao K., et al. Vesicular stomatitis virus-based H5N1 avian influenza vaccines induce potent cross-clade neutralizing antibodies in rhesus macaques. Journal of Virology 2011, 85:4602-4605.
30. Toka F.N., Pack C.D., Rouse B.T. Molecular adjuvants for mucosal immunity. Immunological Reviews 2004, 199:100-112.
31. Veazey R.S., DeMaria M., Chalifoux L.V., Shvetz D.E., Pauley D.R., Knight H.L., et al. Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science 1998, 280:427-431.
32. Wanjalla C.N., Goldstein E.F., Wirblich C., Schnell M.J. A role for granulocyte-macrophage colony-stimulating factor in the regulation of CD8(+) T cell responses to rabies virus. Virology 2012, 426:120-133.
33. Wunderlich G., Moura I.C., del Portillo H.A. Genetic immunization of BALB/c mice with a plasmid bearing the gene coding for a hybrid merozoite surface protein 1-hepatitis B virus surface protein fusion protects mice against lethal Plasmodium chabaudi chabaudi PC1 infection. Infection and Immunity 2000, 68:5839-5845.
34. Xing Z., Tremblay G.M., Sime P.J., Gauldie J. Overexpression of granulocyte-macrophage colony-stimulating factor induces pulmonary granulation tissue formation and fibrosis by induction of transforming growth factor-beta 1 and myofibroblast accumulation. American Journal of Pathology 1997, 150:59-66.